drugset / Trial / NCT00005800
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
Phase 2
Completed
45 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Aventis Pharmaceuticals · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel in treating women who have stage III breast cancer.
Timeline
- Start
- 1999-04
- Primary completion
- 2006-01
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |